| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/12/2012 | CA2804545A1 Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
| 01/12/2012 | CA2804399A1 Anti-ron antibodies |
| 01/12/2012 | CA2804285A1 Bipyridyl derivatives useful for the treatment of kinase - induced diseases |
| 01/12/2012 | CA2804242A1 Cancer therapy using cldn6 target-directed antibodies in vivo |
| 01/12/2012 | CA2804214A1 Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna |
| 01/12/2012 | CA2804210A1 Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna |
| 01/12/2012 | CA2804127A1 Cancer peptide vaccine |
| 01/12/2012 | CA2803900A1 Combinations of kinase inhibitors for the treatment of cancer |
| 01/12/2012 | CA2803880A1 Compounds for the inhibition of cellular proliferation |
| 01/12/2012 | CA2803188A1 Lipid-conjugated antibodies |
| 01/12/2012 | CA2803113A1 Treatment of blood cancer |
| 01/12/2012 | CA2802443A1 Vaccine compositions based on sticholysin encapsulated in liposomes |
| 01/12/2012 | CA2802216A1 Tetrahydrocarboline derivative |
| 01/11/2012 | EP2405015A2 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 01/11/2012 | EP2405002A1 Compositions and methods for oligonucleotide formulations |
| 01/11/2012 | EP2404997A1 Method for enhancing function of t cell |
| 01/11/2012 | EP2404936A1 Cancer therapy using CLDN6 target-directed antibodies in vivo |
| 01/11/2012 | EP2404927A2 Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| 01/11/2012 | EP2404925A1 New all trans platinum (IV) complexes, their preparation and their use as antitumor agents |
| 01/11/2012 | EP2404907A1 Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| 01/11/2012 | EP2404895A1 Calixarene-based peptide conformation mimetics, methods of use, and methods of making |
| 01/11/2012 | EP2404894A1 Mevalonic Acid Derivatives |
| 01/11/2012 | EP2404614A1 Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
| 01/11/2012 | EP2404608A1 Combination use of cholestanol derivative |
| 01/11/2012 | EP2404603A1 Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases |
| 01/11/2012 | EP2404602A1 Hedgehog pathway antagonists to treat cancer |
| 01/11/2012 | EP2404598A1 Amino acid-conjugated cyanoacrylate polymer particles |
| 01/11/2012 | EP2404597A1 NOS-inhibitor L-NIL for use in chronic lung diseases |
| 01/11/2012 | EP2404596A1 Kit for Cancer Treatment and Pharmaceutical Composition for Cancer Treatment |
| 01/11/2012 | EP2404594A1 Compositions comprising docetaxel with increased stability and methods for preparation thereof |
| 01/11/2012 | EP2403945A2 Rna molecules and therapeutic uses thereof |
| 01/11/2012 | EP2403943A1 Vangl1 peptides and vaccines including the same |
| 01/11/2012 | EP2403877A1 Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient |
| 01/11/2012 | EP2403871A1 Antibodies and epitopes specific to misfolded prion protein |
| 01/11/2012 | EP2403857A1 Thienopyrimidine as cdc7 kinase inhibitors |
| 01/11/2012 | EP2403856A1 Methylenedioxybenzo [i]phenanthridine derivatives used to treat cancer |
| 01/11/2012 | EP2403855A1 Carbazole linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof |
| 01/11/2012 | EP2403854A1 Sulfonylated tetrahydroazolopyrazines and their use as medicinal products |
| 01/11/2012 | EP2403853A1 Pyrrolopyrimidines used as kinase inhibitors |
| 01/11/2012 | EP2403833A1 8-substituted quinolines and related analogs as sirtuin modulators |
| 01/11/2012 | EP2403832A1 N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| 01/11/2012 | EP2403539A2 Methods and systems for treatment and/or diagnosis |
| 01/11/2012 | EP2403530A2 Engineered proteins with high affinity for dota chelates |
| 01/11/2012 | EP2403513A2 Fractions of wheat germ ferment |
| 01/11/2012 | EP2403502A1 Medicinal cosmetic lipoatrophy |
| 01/11/2012 | EP2403499A2 Methods and compositions useful in treating cancer and reducing wnt mediated effects in a cell |
| 01/11/2012 | EP2403497A1 Compounds, compositions and use for anticancer therapy |
| 01/11/2012 | EP2403496A1 Compounds and methods for treating cancer and viral infections |
| 01/11/2012 | EP2403494A2 Kinase protein binding inhibitors |
| 01/11/2012 | EP2403492A1 Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak) |
| 01/11/2012 | EP2403491A2 Alkylglycerols and alkoxyglycerols for increasing endogenous plasmalogen levels in mammals |
| 01/11/2012 | EP2403341A1 Lung cancer treatment |
| 01/11/2012 | EP2157971B1 Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer |
| 01/11/2012 | EP2084125B1 Aminobenzocycloheptene derivatives, methods for preparing the same and uses thereof in therapy |
| 01/11/2012 | EP2083806B1 Use of an anti-cancer compound |
| 01/11/2012 | EP2027115B1 Dioxaspiroketal derivatives, process for their preparation and uses thereof |
| 01/11/2012 | EP1948215B1 MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof |
| 01/11/2012 | EP1881983B1 Pyrrolopyridines useful as inhibitors of protein kinase |
| 01/11/2012 | EP1846406B9 Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer |
| 01/11/2012 | EP1819708B1 Substituted pteridines for treating inflammatory diseases |
| 01/11/2012 | EP1802591B1 Quinazoline derivatives |
| 01/11/2012 | EP1750703B1 Method for reducing gastrointestinal toxicity due to the administration of tegafur |
| 01/11/2012 | EP1572074B1 Stabilized synthetic immunogen delivery system |
| 01/11/2012 | EP1511845B1 Immunostimulatory oligonucleotides and uses thereof |
| 01/11/2012 | EP1402070B1 Methods for the diagnosis of cancer based on the obcam and ntm genes |
| 01/11/2012 | CN1948483B SiRNA for inhibiting human Rabj gene expression and its application |
| 01/11/2012 | CN1948482B Antisensedigonucleotides sequence for inhibiting human Rabj gene expression and its application |
| 01/11/2012 | CN1846712B Cinobufagin emulsion for injection and its preparation process |
| 01/11/2012 | CN1767078B Preparation of radium-223, physically accepted preparation and kit |
| 01/11/2012 | CN1642542B Angiogenesis inhibitors |
| 01/11/2012 | CN102317469A GNAQ mutations in melanoma |
| 01/11/2012 | CN102317319A Human antibodies aganist tissue factor. |
| 01/11/2012 | CN102317314A Polypeptides that bind TRAIL-RI and TRAIL-R2 |
| 01/11/2012 | CN102317296A Fused aromatic PTP-1B inhibitors |
| 01/11/2012 | CN102317293A RAF inhibitors and their uses |
| 01/11/2012 | CN102317291A Fused pyrimidines |
| 01/11/2012 | CN102317290A STAT3 inhibitors and therapeutic methods using the same |
| 01/11/2012 | CN102317282A Hetero ring derivative |
| 01/11/2012 | CN102317281A Pyrimidinones as casein kinase ii (CK2) modulators |
| 01/11/2012 | CN102317276A Pharmaceutical compositions of 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate |
| 01/11/2012 | CN102317269A Novel amino azaheterocyclic carboxamides |
| 01/11/2012 | CN102317268A 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors |
| 01/11/2012 | CN102317266A 6-phenylpyrimidinones as PIM modulators |
| 01/11/2012 | CN102317257A Process for the preparation of asymmetrical bis(thiosemicarbazones) |
| 01/11/2012 | CN102316931A Alkylamido compounds and uses thereof |
| 01/11/2012 | CN102316902A Glutathione-based drug delivery system |
| 01/11/2012 | CN102316877A Methods of treating a meiotic kinesin-associated disease |
| 01/11/2012 | CN102311986A Cells producing antibody compositions |
| 01/11/2012 | CN102311956A Specific base modification antisense nucleotide chain and application thereof |
| 01/11/2012 | CN102311868A Method for extracting krill oil rich in phospholipids and neutral lipid without using solvent |
| 01/11/2012 | CN102311509A Extracting method of sweet potato stem leaf polysaccharide |
| 01/11/2012 | CN102311502A Fusion protein used for inhibiting regeneration or growth of blood vessel and medical treatment application thereof |
| 01/11/2012 | CN102311499A Humanized monoclonal antibody for treating cancer, and preparation method and application thereof |
| 01/11/2012 | CN102311493A Peptide inhibiting telomerase activity, its preparation method and application |
| 01/11/2012 | CN102311492A Non-natural fully D-type snake venom cathelicidin antibacterial peptide and derivative, preparation method as well as application thereof |
| 01/11/2012 | CN102311485A Polypeptide with neovascularization suppression effect and application thereof |
| 01/11/2012 | CN102311477A Preparation method and application of monoglucosidated ergosterol |
| 01/11/2012 | CN102311476A Toonapubesin C and preparation method as well as application thereof |
| 01/11/2012 | CN102311475A New compound separated from Mythic Fungus, preparation method thereof and medicinal purpose thereof |
| 01/11/2012 | CN102311473A Toonapubesic aldehyde and preparation method as well as application thereof |